consultants believe that those with ibs could have changes within their intestinal microorganisms, leading them to consider targeting these gut microorganisms to treat the condition.
they selected to study rifaximin as a result of it's minimally absorbed and stays within the gut, that they thought it may perform higher than the antibiotics widely absorbed by the body, that have made mixed results for ibs patients.
pimentel and colleagues conducted 2 parallel studies of the antibiotic. in each trials, called target one and target two, they assigned 600 ibs patients with mild to moderate diarrhea and bloating to require either a 550-milligram dose of rifaximin or a placebo 3 times every day for 2 weeks.
the patients reported on their symptoms and were followed for ten weeks when the 2-week doses.
for the 2 studies combined, forty. 7% of these taking the drug had adequate relief of their symptoms throughout the primary four weeks when treatment, other then barely thirty one. 7% of these on placebo.
whereas forty. 2% of these on the drug had relief from bloating, thirty. 3% of these within the placebo cluster did.
the drug, pimentel says, "passes through the gut and gets rid of the bacteria within the tiny bowel that are believed to cause the issues. "
the studies were funded by salix pharmaceuticals inc., that makes rifaximin. pimentel serves as a consultant to salix and serves on its scientific advisory board. he discovered the use of the antibiotic for ibs. cedars-sinai holds the patent and has licensed the rights to salix.
salix has applied for fda approval of the drug for the non-constipation kind of ibs and that ibs-related bloating, says mike freeman, company spokesman.
0 komentar:
Posting Komentar